

Gilead Sciences

Nordic Fellowship Programme

2024

To encourage the development, exploration and dissemination of new ideas in patient-centered care

Application is open

Gilead Sciences Nordic Fellowship Programme in support of local innovation and best practices to ultimately improve patient care in three therapy areas – Virology (HIV, HCV, HDV), Cell Therapy and Oncology. We look forward to receiving completed applications by the **15th of July, 2024**.



Gilead Sciences proudly announces the twelfth year of the **Nordic Fellowship Programme 2024**

The aim of Gilead Sciences Nordic Fellowship Programme is to support healthcare organisations and/or academic institutions to develop innovative, high-impact projects that deliver measurable benefits to patients, healthcare providers and communities impacted by Gilead’s therapeutic areas of expertise.

Since 2013, the programme has funded more than 100 Nordic projects, leaving an important legacy in these areas. Applications are invited from healthcare organisations and/or academic institutions who are seeking funding for a project that aligns with the goals of the programme.

About the programme 2024	2
Timeline	3
Eligibility criteria	4
Guidance for applicants	5
How to apply	5
Judging criteria	6
Successful applications	8

This year’s funding will be 85 000 euro for each of the three therapy areas – Virology (HIV, HCV, HDV), Cell Therapy, and Oncology. The projects supported by the Gilead Sciences Nordic Fellowship Programme are independent of the use of any therapeutic agent.

Please note, proposals meeting one of the following criteria cannot be funded under the fellowship programme:

- a clinical trial under the Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use (EU regulation)
- research related to Gilead products

The judging committee consists of senior representatives from Gilead Sciences Nordic Affiliates, Medical, Regulatory, Legal and Finance departments. Gilead’s General Manager in the Nordics will participate in the judging sessions as a nonvoting member.


Applications will be accepted from the 17th of May until the 15th of July, 2024. We anticipate the decisions will be communicated to all applicants by end of September 2024.

To apply

Apply through the Gilead Sciences Nordic webpage:
www.gilead.se/our-purpose/corporate-giving/gilead-nordic-fellowship



Timeline



Eligibility criteria 2024

by therapy area

To be awarded funding, applicants are required to demonstrate how their innovative, high-impact projects to be conducted in the Nordics, meets this year's criteria within the therapy areas as outlined below:

Virology (HIV, HCV, HDV)

- Projects aiming for ending epidemics, e.g. testing (*including broad blood-borne-viruses testing*), linkage to and retention in care
- Understanding burden of disease and patient characteristics, e.g. quality of life, disease progression
- Risk assessment, identification, and management of comorbidities within HIV

Cell Therapy

- Haematology with focus areas B-cell lymphomas, ALL and multiple myeloma:
 - Document unmet need or improve patient outcomes using health registries
 - Advance patient management, diagnosing or precision health approaches including the use of artificial intelligence approaches
- Basic, pre-clinical and translational research to enhance the understanding of cancer-immunology in cell therapy

Oncology

- Basic, pre-clinical and translational research advancing the understanding of:
 - Tumor-intrinsic pathways in tumor cell death
 - Immune-mediated tumor killing
 - The tumor permissive microenvironment
- In oncology, understand scientific mechanism of:
 - Trop-2 on disease progression or treatment outcomes
 - Drug resistance
 - Blood-brain-barrier disruption in patients with brain metastasis (*breast cancer and/or lung cancer*)
- Managing patient care (*including adverse events in patients with metastatic epithelial cell malignancies*).
- Real-world evidence for prevalence, incidence, and treatment outcomes in patients with metastatic breast cancer, urothelial cancer and/or lung cancer

Guidance for applicants

For the twelfth consecutive year, Gilead Sciences proudly invites healthcare organisations and/or academic institutions to seek funding from the Gilead Sciences Nordic Fellowship Programme. Applications are accepted from **May 17th to July 15th, 2024.**

The following information is intended to provide guidance on how to submit your application to the programme.

1 How do I apply?

Go to: www.gilead.se/our-purpose/corporate-giving/gilead-nordic-fellowship

Or scan the QR code.



First register, and then choose the following grant and program type:

1. Therapeutic Area:

(Select one of the following)

- HIV/AIDS
- Liver disease
- HDV or HCV
- Hematology/Oncology
(including cell therapy)

2. Grant Type: **Medical/Scientific**

3. Program Type: **Fellowship/Scholarships**

4. Credit Type: **Unaccredited**

5. Tax status: **Not for profit**

Proof of organization: this document would include the unique organization identifier and is usually provided by the government. If the document does not exist, you can upload a blank document.

2 Can I apply for 100% of project funding to come from the Nordic Fellowship Programme?

Yes, you can apply for 100% funding or partial funding of the project.

3 Do I consider whether my proposed project comprises an interventional trial?

Yes, if your project meets the definition of a clinical study and/or clinical trial in article 2.2 (1) and (2) of the EU Regulation, it will not be funded under the fellowship programme. Any such clinical study/clinical trial may instead be sent to nordicfellowship@gilead.com for consideration as an investigator sponsored trial.

Clinical trial means a clinical study which fulfils any of the following conditions:

1. Assignment of the subject to a particular therapeutic strategy is decided in advance and does not fall within normal clinical practice (*i.e.*, the treatment regime typically followed to treat, prevent, or diagnose a disease or a disorder) of the member state concerned.
2. The decision to prescribe the investigational medicinal products is taken together with the decision to include the subject in the clinical study.
3. Diagnostic or monitoring procedures in addition to normal clinical practice are applied to the subjects.

4 What does my application need to include? – what are the judging criteria?

- Clear purpose and rationale for the project
- Objectives and overview of the project, including specific goals and population to be targeted
- Description of how the project achieves innovation
- Information regarding the applicant's capacity to initiate and implement the project in a timely manner
- Methodology:
 - Specific, measurable, achievable, realistic and time sensitive project milestones and action steps required to meet project goals
 - Process for data collection and analysis, including which staff members will analyse the data
 - Deliverables in terms of measurable objectives and outcomes
 - Clear description of project outcome data and how they will improve patient care including relevant patientrelated outcome data, if applicable (*which should ideally be measured using validated tools*)
 - Methodology for the collection and reporting of cost-effectiveness data, if applicable
- Outline of your publication plans
- Clear details of the budget

continued. **Guidance for applicants**

5

Do I need to include references in my application?

Appropriate citations should be provided for all statistics and references should be listed in the application.

6

What information should I include in the budget?

All applications must include full details of the amount of funding being requested. A justification must be provided for all items in the budget table on the application. Funding requests for additional staff can only be considered for project dedicated staff time to execute the project. Applications without an appropriately completed budget cannot be considered.

7

Can I apply for support on a currently ongoing project?

Yes, if the funding will be used to extend or expand an existing project that will be completed before the end of December 2026 and the proposal meets the criteria. The application must highlight why additional funding is required for the completion of the project. This must be explained in the application form.

8

Can I recall an application to make changes?

Yes, on the condition that the application is resubmitted by the final deadline on **July 15th, 2024**. To recall a submitted application, email: nordicfellowship@gilead.com

9

Will I receive feedback once applications have been submitted?

All submissions will be reviewed prior to judging for completeness of applications. If, for any reason, further clarity is needed on an application, an email will be sent to the applicant to seek clarification (*and, if needed, resubmission*) before the closing date.

If you have any questions regarding the application process or more specific application enquiries, please send them to nordicfellowship@gilead.com

What can I expect if I have a successful application?

All successful applicants will be notified by end September 2024 and will be asked to sign a grant agreement letter. The Grant Agreement Letter summarises the core requirements of the grant award, the amount of grant and the responsibilities for each party including the right of Gilead Sciences to review any potential publications from the project.

Successful applicants will:

- Provide Gilead Sciences with standardised interim report on their project concerning the progress of the project 12 months after project initiation. In the event of the project has not commenced or adequately progressed, Gilead Sciences in its sole discretion may request payback of some or all the funding.
- Provide Gilead Sciences with a final report on the project which includes the final findings and conclusions no later than at completion of the project. *(A standardised reporting template for interim and final reports will be made available by Gilead Sciences.)*
- Attend a Gilead Sciences organised meeting in 2027 to share best practice *(BPSE meeting)*, with an oral presentation describing their project results and best practices.
- Strive to make the results generated during this fellowship publicly available in some format, e.g. poster, manuscript etc. All draft material must be supplied to Gilead Sciences for review at least 10 working days prior to any public communication. Gilead Sciences should be acknowledged in any publication in connection with the grant stating that *“This has been supported by an unrestricted grant from Gilead Sciences”*. Please send the draft material to: rebecca.frigell@gilead.com

When will funding be provided?

On the successful award of a Fellowship grant, Gilead Sciences will state which items of the project will be supported. Full project payment will be made by year end 2024 and project are expected to be completed within 24 months.

Funding decision is communicated via email to all applicants, and for the approved projects, payment is electronically transmitted upon full contract execution.

Applicants who are unsuccessful 2024 are welcome to re-apply next year.

The judging panel can supply feedback for unsuccessful applicants within 6 weeks of the judging decision. This will be available on request only.

Welcome to apply!



Gilead Sciences Nordic Fellowship Programme
Gilead Sciences, Hemvärnsgatan 9, 171 54 Solna, Sweden. Tel 08-505 718 00

Your name, email address and workplace are processed by Gilead Sciences Sweden AB ("GSSAB").
You have the right to correct, amend, or delete information about yourself at any time.

Information on how Gilead processes and shares personal data, including data transfers
to third-party organizations and outside the European Economic Area, can be found
www.gilead.se/Privacy/Privacy-Statement.